Harvard Apparatus Regenerative Technology Files 8-K

TL;DR

HART files 8-K for material agreement & equity sales. Details TBD.

AI Summary

On August 19, 2024, Harvard Apparatus Regenerative Technology, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and filed financial statements and exhibits. The filing does not specify the nature of the agreement or the details of the equity sales.

Why It Matters

This 8-K filing indicates significant corporate activity, including a material definitive agreement and equity sales, which could impact the company's financial standing and future operations.

Risk Assessment

Risk Level: medium — The filing indicates a material definitive agreement and unregistered equity sales, which can introduce financial and operational risks if not managed properly.

Key Players & Entities

• Harvard Apparatus Regenerative Technology, Inc. (company) — Registrant
• August 19, 2024 (date) — Date of earliest event reported
• Biostage, Inc. (company) — Former company name

FAQ

Key Financial Figures

• $5.0 million — gregate purchase price of approximately $5.0 million and a purchase price per share of $3.60
• $3.60 — llion and a purchase price per share of $3.60 (the "Private Placement"). The Purcha

Filing Documents

• form8-k.htm (8-K) — 42KB
• ex10-1.htm (EX-10.1) — 177KB
• 0001493152-24-033401.txt ( ) — 424KB
• hrgn-20240819.xsd (EX-101.SCH) — 3KB
• hrgn-20240819_lab.xml (EX-101.LAB) — 33KB
• hrgn-20240819_pre.xml (EX-101.PRE) — 22KB
• form8-k_htm.xml (XML) — 3KB

From the Filing

UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2024 HARVARD APPARATUS REGENERATIVE TECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-35853 45-5210462 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 84 October Hill Road , Suite 11 , Holliston , MA (Address of principal executive offices) Registrant's telephone number, including area code: (774) 233-7300 (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: None Title of each class Trading Symbol(s) Name of each exchange on which registered N/A N/A N/A Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 1.01. Entry Into a Material Definitive Agreement. On August 19, 2024, Harvard Apparatus Regenerative Technology, Inc. (the "Company") entered into a Securities Purchase Agreement with an investor (the "Investor") pursuant to which the Investor agreed to purchase in a private placement an aggregate of 1,388,888 shares of common stock for the aggregate purchase price of approximately $5.0 million and a purchase price per share of $3.60 (the "Private Placement"). The Purchase Agreements include customary representations, warranties and covenants. Additionally, the Purchase Agreement requires the Company to increase the size of its Board of Directors (the "Board") by one member, to appoint a designee selected by the Investor to the Board, and to take certain actions to ensure that the designee remains on the Board. The Company also agreed to use its reasonable best efforts to obtain approval from its stockholders at the next annual meeting of stockholders to amend the Company's Amended and Restated Certificate of Incorporation (the "Charter") to eliminate classification of directors and to amend the Charter and the Company's Third Amended and Restated Bylaws to permit special stockholder meetings to be called by holders of at least 35% of the Company's voting power. The representations, warranties and covenants contained in the Purchase Agreement were made solely for the benefit of the parties to the Purchase Agreement. In addition, such representations, warranties and covenants (i) are intended as a way of allocating the risk between the parties to the Purchase Agreement and not as statements of fact, and (ii) may apply standards of materiality in a way that is different from what may be viewed as material by stockholders of, or other investors in, the Company. Accordingly, the form of Purchase Agreement is included with this filing only to provide investors with information regarding the terms of transaction, and not to provide investors with any other factual information regarding the Company. Stockholders should not rely on the representations, warranties and covenants or any descriptions thereof as characterizations of the actual state of facts or condition of the Company or any of its subsidiaries or affiliates. Moreover, information concerning the subject matter of the representations and warranties may change after the date of the Purchase Agreement, which subsequent information may or may not be fully reflected in public disclosures. The foregoing summary of the terms of the Purchase Agreement is subject to, and is qualified in its entirety by, the terms of the Purchase Agreement, which is filed herewith as Exhibit 10.1 and is incorporated into this Item 1.01 by reference. Item 3.02. Unregistered Sale of Equity Securities. The information contained above in Item 1.01 related to the Private Placement is hereby incorporated by reference into this Item 3.02. The shares of common stock issued to the Investor were sold and issued without registra

View Full Filing

View this 8-K filing on SEC EDGAR